Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
Authors:
- Beatriz Rey-BúaBRBeatriz Rey-Búa
- Mónica CabreroMCMónica Cabrero
- Leyre BentoLBLeyre Bento
- Juan MontoroJMJuan Montoro
- Mariana Bastos-OreiroMBMariana Bastos-Oreiro
- Rocío ParodyRPRocío Parody
- Lucrecia YañezLYLucrecia Yañez
- Oriana Lopez-GodinoOLOriana Lopez-Godino
- Joud ZanabiliJZJoud Zanabili
- Pilar HerreraPHPilar Herrera
- Gonzalo GutierrezGGGonzalo Gutierrez
- Ariadna PerezAPAriadna Perez
Open Access
Abstract
Background: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored. Methods: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival. Results: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31–67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2–9.6). Conclusions: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL.Keywords
This publication has 39 references indexed in Scilit:
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology ResourceJournal of Clinical Oncology, 2013
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular LymphomaJournal of Clinical Oncology, 2008
- Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeLeukemia, 2007
- Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2007
- Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology StudyJournal of Clinical Oncology, 2007
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974